Glizamide M 60 Tablet contains Gliclazide 60mg + Metformin 500mg, a combination oral antidiabetic therapy designed for type 2 diabetes management. Gliclazide stimulates insulin secretion from pancreatic beta cells, while Metformin improves insulin sensitivity and reduces hepatic glucose production, providing complementary glycemic control.
This tablet falls under the diabetes care segment, offering a convenient dual-action therapy for patients requiring combination treatment. Its formulation supports postprandial and fasting blood sugar management efficiently, helping achieve optimal glycemic targets.
Glizamide M 60 Tablet is widely prescribed by endocrinologists, general physicians, hospitals, and clinics, making it a high-demand product for PCD pharma franchise and B2B distribution. Its dual-action mechanism ensures patient adherence, repeat prescriptions, and long-term therapeutic benefit.
For PCD pharma franchise and B2B partners, Glizamide M 60 Tablet represents a profitable and in-demand opportunity. With steady hospital, clinic, and retail demand, it is ideal for domestic distribution, export, and third-party manufacturing, ensuring sustainable business growth and attractive margins.